WO2008120761A1 - ヘテロアリール誘導体 - Google Patents

ヘテロアリール誘導体 Download PDF

Info

Publication number
WO2008120761A1
WO2008120761A1 PCT/JP2008/056217 JP2008056217W WO2008120761A1 WO 2008120761 A1 WO2008120761 A1 WO 2008120761A1 JP 2008056217 W JP2008056217 W JP 2008056217W WO 2008120761 A1 WO2008120761 A1 WO 2008120761A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
acceptable salt
general formula
represents hydrogen
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056217
Other languages
English (en)
French (fr)
Inventor
Masato Matsuoka
Tatsuya Oyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to CA002682377A priority Critical patent/CA2682377A1/en
Priority to US12/593,566 priority patent/US8217031B2/en
Priority to JP2009507542A priority patent/JP5206669B2/ja
Priority to AU2008233587A priority patent/AU2008233587B2/en
Priority to EP20080739335 priority patent/EP2141168A4/en
Priority to MX2009010559A priority patent/MX2009010559A/es
Priority to BRPI0809483-7A priority patent/BRPI0809483A2/pt
Priority to CN2008800104751A priority patent/CN101646678B/zh
Publication of WO2008120761A1 publication Critical patent/WO2008120761A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

　本発明としては、例えば、次の一般式［１］で表される化合物（以下、本発明化合物という。）又はその医薬上許容される塩を挙げることができる。 　　【化１】 　一般式［１］中、Ｘ、Ｙは、一方がＣＨで他方が酸素又は硫黄を表し、Ｒは水素などを表し、Ｚは水素などを表し、Ａｒはフェニルなどを表し、ｎは１又は２を、ｍは１又は２を、それぞれ表す。但し、ｎが２であって、かつ、ｍが２である化合物を除く。 　また、本発明化合物又はその医薬上許容される塩を有効成分として含有する医薬組成物は、うつ病、パニック障害、不安症、強迫性障害、慢性疼痛、線維筋痛症、肥満、腹圧性尿失禁、過活動膀胱などの予防剤又は治療剤として用いることができる。
PCT/JP2008/056217 2007-03-30 2008-03-28 ヘテロアリール誘導体 Ceased WO2008120761A1 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002682377A CA2682377A1 (en) 2007-03-30 2008-03-28 Heteroaryl derivatives
US12/593,566 US8217031B2 (en) 2007-03-30 2008-03-28 Heteroaryl derivatives
JP2009507542A JP5206669B2 (ja) 2007-03-30 2008-03-28 ヘテロアリール誘導体
AU2008233587A AU2008233587B2 (en) 2007-03-30 2008-03-28 Heteroaryl derivative
EP20080739335 EP2141168A4 (en) 2007-03-30 2008-03-28 HETEROARYLATED DERIVATIVES
MX2009010559A MX2009010559A (es) 2007-03-30 2008-03-28 Derivados de heteroarilo.
BRPI0809483-7A BRPI0809483A2 (pt) 2007-03-30 2008-03-28 Derivados heteroarílicos
CN2008800104751A CN101646678B (zh) 2007-03-30 2008-03-28 杂芳基衍生物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007094548 2007-03-30
JP2007-094548 2007-03-30
JP2007146039 2007-05-31
JP2007-146039 2007-05-31

Publications (1)

Publication Number Publication Date
WO2008120761A1 true WO2008120761A1 (ja) 2008-10-09

Family

ID=39808341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056217 Ceased WO2008120761A1 (ja) 2007-03-30 2008-03-28 ヘテロアリール誘導体

Country Status (11)

Country Link
US (1) US8217031B2 (ja)
EP (1) EP2141168A4 (ja)
JP (1) JP5206669B2 (ja)
KR (1) KR20090130094A (ja)
AU (1) AU2008233587B2 (ja)
BR (1) BRPI0809483A2 (ja)
CA (1) CA2682377A1 (ja)
MX (1) MX2009010559A (ja)
MY (1) MY151072A (ja)
RU (1) RU2009140095A (ja)
WO (1) WO2008120761A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094289A1 (en) * 2009-02-20 2010-08-26 Aarhus Universitet Allosteric binding compounds
JP2022517621A (ja) * 2019-01-17 2022-03-09 ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド ホステムサビルの調製方法
JP2024528614A (ja) * 2021-07-21 2024-07-30 スベレント セラピューティクス， インク． ニトリルｓｕｍｏ阻害剤及びその使用
US12612414B2 (en) 2022-07-21 2026-04-28 Cit Therapeutics, Inc. Nitrile SUMO inhibitors and uses thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
WO2015035223A1 (en) 2013-09-09 2015-03-12 Peloton Therapeutics, Inc. Aryl ethers and uses thereof
ES2737148T3 (es) 2013-12-16 2020-01-10 Peloton Therapeutics Inc Análogos de sulfona y sulfoximina cíclicos y usos de los mismos
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
WO2016144826A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US9796697B2 (en) 2015-06-12 2017-10-24 Peloton Therapeutics, Inc. Tricyclic inhibitors of HIF-2-alpha and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51149297A (en) * 1975-05-30 1976-12-22 Parcor Production of thienopyridine derivative and treating composition containing same
JPS52294A (en) * 1975-05-28 1977-01-05 Parcor Production of 4*5*6*77 tetrahydroothieno *3*22c** pyridine derivative and treating composition containing same
WO2006004931A2 (en) * 2004-06-30 2006-01-12 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
WO2006082354A1 (en) * 2005-01-07 2006-08-10 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific channels ( sns )

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52294A (en) * 1975-05-28 1977-01-05 Parcor Production of 4*5*6*77 tetrahydroothieno *3*22c** pyridine derivative and treating composition containing same
JPS51149297A (en) * 1975-05-30 1976-12-22 Parcor Production of thienopyridine derivative and treating composition containing same
WO2006004931A2 (en) * 2004-06-30 2006-01-12 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
WO2006082354A1 (en) * 2005-01-07 2006-08-10 Vernalis (R & D) Limited Azacyclic compounds as inhibitors of sensory neurone specific channels ( sns )

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
ANDERSSON KE, UROLOGY, vol. 55, no. 5A, 2000, pages 51 - 57
CHEMISTRY LETTERS, 1980, pages 1389
CLOOS JM, CURR OPIN PSYCHIATRY, vol. 18, no. 1, 2005, pages 45 - 50
DHILLON S ET AL., CNS DRUGS, vol. 20, no. 9, 2006, pages 763 - 790
GROTHE DR ET AL., PHARMACOTHERAPY, vol. 24, no. 5, 2004, pages 621 - 629
HAINER V ET AL., ANN N Y ACAD SCI., vol. 1083, 2006, pages 252 - 269
HETEROCYCLES, vol. 12, 1979, pages 1479
J. CHEM. SOC. PERKIN TRANS., vol. 1, 1986, pages 877 - 884
J. HETEROCYCLIC CHEM., vol. 13, 1976, pages 1347
J. HETEROCYCLIC CHEM., vol. 22, 1985, pages 1011
KAMIJIMA K; AOKI M, EXPERT REV NEUROTHER, vol. 6, no. 7, 2006, pages 945 - 956
KENT JM, LANCET, vol. 355, 2000, pages 911 - 918
MARIAPPAN P ET AL., EUR UROL., vol. 51, no. 1, 2007, pages 67 - 74
ROOKS DS, CURR OPIN RHEUMATOL, vol. 19, no. 2, 2007, pages 111 - 117
See also references of EP2141168A4
SPROULE B.A. ET AL.: "Selective Serotonin Reuptake Inhibitors and CNS Drug Interactions", CLINICAL PHARMACOKINETICS, vol. 33, no. 6, 1997, pages 454 - 471, XP000909466 *
TREMBLAY P; BLIER P, CURR DRUG TARGETS, vol. 7, no. 2, 2006, pages 149 - 158

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010094289A1 (en) * 2009-02-20 2010-08-26 Aarhus Universitet Allosteric binding compounds
JP2022517621A (ja) * 2019-01-17 2022-03-09 ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド ホステムサビルの調製方法
JP7429236B2 (ja) 2019-01-17 2024-02-07 ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド ホステムサビルの調製方法
JP2024528614A (ja) * 2021-07-21 2024-07-30 スベレント セラピューティクス， インク． ニトリルｓｕｍｏ阻害剤及びその使用
US12612414B2 (en) 2022-07-21 2026-04-28 Cit Therapeutics, Inc. Nitrile SUMO inhibitors and uses thereof

Also Published As

Publication number Publication date
JP5206669B2 (ja) 2013-06-12
EP2141168A1 (en) 2010-01-06
AU2008233587B2 (en) 2012-05-17
EP2141168A4 (en) 2011-07-20
AU2008233587A1 (en) 2008-10-09
JPWO2008120761A1 (ja) 2010-07-15
US20100048537A1 (en) 2010-02-25
MY151072A (en) 2014-03-31
KR20090130094A (ko) 2009-12-17
RU2009140095A (ru) 2011-05-10
CA2682377A1 (en) 2008-10-09
US8217031B2 (en) 2012-07-10
BRPI0809483A2 (pt) 2014-09-09
MX2009010559A (es) 2009-10-22

Similar Documents

Publication Publication Date Title
WO2008120761A1 (ja) ヘテロアリール誘導体
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
WO2008121348A3 (en) Peripheral opioid receptor antagonists and uses thereof
TW200615266A (en) Organic compounds
WO2007138472A3 (en) Triazolopyridazine derivatives
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
WO2005116002A3 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2007117465A3 (en) Indazole compounds
EP2371811A3 (en) Azetidinecarboxylic acid derivative and medicinal use thereof
WO2008024497A3 (en) INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2009069764A1 (ja) オピオイド鎮痛剤
WO2007031828A3 (en) Therapeutic pyrrolidines
WO2006078724A3 (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880010475.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739335

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009507542

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008233587

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12009501819

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 12593566

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2682377

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 5748/CHENP/2009

Country of ref document: IN

Ref document number: MX/A/2009/010559

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2008233587

Country of ref document: AU

Date of ref document: 20080328

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008739335

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097022819

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009140095

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0809483

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090930